EPIZYME INC (EPZM) Stock News

USA - NASDAQ:EPZM - US29428V1044 - Common Stock

1.47 USD

-0.02 (-1.34%)

Last: 8/11/2022, 8:00:01 PM

1.47 USD

0 (0%)

After Hours: 8/11/2022, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EPZM Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Benzinga

Epizyme: Q2 Earnings Insights

3 years ago - By: Epizyme, Inc.

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

3 years ago - By: Weiss Law

SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.

3 years ago - By: InvestorPlace

Why Is Epizyme (EPZM) Stock Up 75% Today?

3 years ago - By: Benzinga

Why Epizyme Shares Are Soaring Today

3 years ago - By: Kahn Swick & Foti, LLC

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

3 years ago - By: Kahn Swick & Foti, LLC

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

3 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen

3 years ago - By: InvestorPlace - Mentions: AXSM TSLA

Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal

3 years ago - By: Halper Sadeh LLP

EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders

3 years ago - By: InvestorPlace - Mentions: BRQS EVFM AGRX TENX ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

3 years ago - By: Epizyme, Inc. - Mentions: OTC

Ipsen to acquire Epizyme, expanding its portfolio in oncology

3 years ago - By: Epizyme, Inc.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting